Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes.

Saved in:
Bibliographic Details
Title: Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes.
Authors: Medford AJ; Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA., Velimirovic M; Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH, USA., Gefen Y; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA., Niemierko A; Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA., Gerratana L; Department of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy., Davis AA; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Clifton K; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Keenan J; Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA., Podany E; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Hensing WL; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Reduzzi C; Weill Cornell Medicine, 420 E 70 th St, LH 204, New York, NY, 10021, USA., Dai CS; Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Kiedrowski LA; Department of Medical Affairs, Guardant Health, Redwood City, CA, USA., Spring LM; Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA., Ellisen LW; Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA., Doebele RC; Rain Therapeutics, Newark, CA, USA., Cristofanilli M; Weill Cornell Medicine, 420 E 70 th St, LH 204, New York, NY, 10021, USA., Getz G; Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA., Bardia A; David Geffen School of Medicine at UCLA & UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, 90024, USA. ABardia@mednet.ucla.edu.
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2025 Aug; Vol. 212 (3), pp. 437-447. Date of Electronic Publication: 2025 May 29.
Publication Type: Journal Article
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1573-7217
DOI:10.1007/s10549-025-07710-w